Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy 2.0

Monoclonal antibodies (mAbs) are among the most specialised molecules for the recognition and capture of specific analytes. Hundreds of thousands of mAbs have been generated for a large number of different antigens with increasing affinity and specificity and are available for the most diverse purpo...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (112 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 02902nam-a2200685z--4500
001 993546014704498
005 20231214133413.0
006 m o d
007 cr|mn|---annan
008 202203s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000045251 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/79602 
035 |a (EXLCZ)995400000000045251 
041 0 |a eng 
100 1 |a Ruvo, Menotti  |4 edt 
245 1 0 |a Monoclonal Antibodies and Their Functional Fragments in Research, Diagnosis and Therapy 2.0 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (112 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Monoclonal antibodies (mAbs) are among the most specialised molecules for the recognition and capture of specific analytes. Hundreds of thousands of mAbs have been generated for a large number of different antigens with increasing affinity and specificity and are available for the most diverse purposes. Many of them have been validated as irreplaceable agents for diagnosis and therapy or as unique reagents for research. Others have been developed using emerging technologies that avoid the need for animal immunisation. This short book strives to gather the perspective view of the various contributing authors and to survey the new strategic assets adopted to generate novel monoclonal antibodies or surrogates, such as Fab, Fab2, ScFv and nanobodies, which have an increasing impact in biomedicine as therapeutic or diagnostic assets in various diseases. 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
650 7 |a Biology, life sciences  |2 bicssc 
653 |a PRAME 
653 |a mAb 
653 |a bio-layer interferometry 
653 |a epitope identification 
653 |a monoclonal antibody 
653 |a free radical 
653 |a protein aggregation 
653 |a oxidation 
653 |a excipient 
653 |a foot-and-mouth disease virus 
653 |a type O 
653 |a type A 
653 |a phage display 
653 |a antibody 
653 |a competitive ELISA 
653 |a atherosclerosis 
653 |a nano-emulsion 
653 |a magnetic resonance imaging 
653 |a stealth 
653 |a human antibody 
653 |a C. auris 
653 |a candidiasis 
653 |a multidrug resistance 
653 |a monoclonal antibodies 
653 |a universal antibodies 
653 |a cell wall 
653 |a passive immunization 
653 |a cell-based panning 
653 |a semi-automated cell panning 
653 |a FGFR3-specific antibody 
776 |z 3-0365-3165-3 
776 |z 3-0365-3164-5 
700 1 |a Sandomenico, Annamaria  |4 edt 
700 1 |a Ruvo, Menotti  |4 oth 
700 1 |a Sandomenico, Annamaria  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:53:06 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338066820004498&Force_direct=true  |Z 5338066820004498  |b Available  |8 5338066820004498